



(51) International Patent Classification:

C12N 15/867 (2006.01) A61K 38/17 (2006.01)
A61K 35/76 (2015.01) A61P 35/00 (2006.01)
A61K 38/16 (2006.01) C12N 7/00 (2006.01)

(21) International Application Number:

PCT/US2024/048301

(22) International Filing Date:

25 September 2024 (25.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/540,336 25 September 2023 (25.09.2023) US
63/618,878 08 January 2024 (08.01.2024) US

(71) Applicant: **KELONIA THERAPEUTICS, INC.**

[US/US]; Suite C, 135 William T. Morrissey Boulevard,
Boston, MA 02125 (US).

(72) Inventors: **FRIEDMAN, Kevin, M.**; 525 East 2nd Street,

Boston, MA 02127 (US). **PERKINS, Molly, R.**; 64 Bradlee
Rd., Milton, MA 02186 (US). **DOBSON, Connor, S.**;
1270 4th St NE, Apt 743, Washington, DC 20002 (US).
SAZINSKY, Stephen, L.; 58 Westland Ave., Winchester,
MA 01890 (US). **CONTRASTANO, Shannon, G.**; 8 Orris
St. #2, Auburndale, MA 02466 (US). **THOMPSON BEU-**

RA, Emily; 59 Marshall Avenue, Mansfield, MA 02048
(US). **AHONEN, Cory**; 7 Lucent Drive, Lebanon, NH
03766 (US). **AVERY, Andrew**; 7 Lucent Drive, Lebanon,
NH 03766 (US).


(74) Agent: **BRYAN, Erin, E.**; Morse, Barnes-Brown & Pendle-
ton, P.C., CityPoint, 480 Totten Pond Road, 4th Floor,
Waltham, MA 02451 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: COMPOSITIONS FOR TREATING CANCER

FIGURE 5A



(57) Abstract: The present disclosure provides compositions and methods comprising recombinant particles suitable for specifically delivering one or more chimeric antigen receptors to immune effector cells *in vivo*.

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*